Research programme: fms-like tyrosine kinase 3/cyclin dependent kinase 4 inhibitors - Amgen

Drug Profile

Research programme: fms-like tyrosine kinase 3/cyclin dependent kinase 4 inhibitors - Amgen

Alternative Names: AM-5992; flt3/CDK4 dual kinase inhibitor - Amgen

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
  • 20 Oct 2013 Pharmacodynamics data for AMG 5992 from a preclinical trial in Acute myeloid leukaemia presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
  • 20 Oct 2013 Preclinical trials in Acute myeloid leukaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top